Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia | China In-Depth | China | 2022
Of the four subtypes of non-Hodgkin’s lymphoma (NHL), diffuse large B-cell lymphoma (DLBCL) is the most common in China. Rituximab (Roche’s MabThera, biosimilars) continues to dominate China’s NHL market owing to its favorable and well-established clinical profile, particularly as part of the R-CHOP chemotherapy regimen. However, novel targeted therapies that we expect to launch in the next few years and the label expansion of existing BTK inhibitors, such as ibrutinib (Janssen’s Imbruvica) and zanubrutinib (BeiGene’s Brukinsa), will challenge rituximab’s market dominance. These therapies will expand the Chinese NHL therapy market significantly during the forecast period, despite the launch of cost-effective biosimilars of rituximab, which started in 2019. The high unmet need for effective targeted therapies for NHL in China presents solid commercial opportunity for developers. Additionally, the ongoing reforms in China’s regulatory and access and reimbursement landscape will encourage multinational corporations to enter the market.
QUESTIONS ANSWERED
- How large is China’s drug-treatable NHL population, and how will drug-treatment rates change during the forecast period?
- Which are the most commercially relevant drugs in China’s NHL market and why? What are interviewed experts’ insights into current treatment options?
- What are the market access considerations for key therapies in the NHL pipeline in China? What sales could these agents secure in NHL? What are interviewed experts’ opinions of key emerging therapies?
- What are the key drivers and constraints in China’s NHL therapy market, and how will the market evolve over the forecast period?
CONTENT HIGHLIGHTS
Release date: December 2022.
Geographies: China.
Primary research: Country-specific qualitative and quantitative insights driven by 5 thought-leader interviews and 75 surveys with hematologist-oncologists. Supported by survey data collected for this and other Clarivate research.
Epidemiology: Diagnosed incidence of NHL in urban versus rural China; clinically relevant and commercially relevant drug-treatable populations.
Forecast: Annualized, 10-year, drug-level sales and patient share of key NHL therapies through 2031, based on primary and secondary market research to formulate bottom-up assumptions.
Emerging therapies: Phase III / PR: 15+ drugs; Phase II: 15+ drugs; coverage of select Phase I products.
PRODUCT DESCRIPTION
China In-Depth offers comprehensive market intelligence, including world-class epidemiology, keen insight into the China-specific A&R environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research. This solution helps companies gauge commercial outlooks and optimize clinical development, subpopulation targeting, physician messaging, and overall long-term strategy in China.
